inVentiv Health announces 'significant' investment, cancels IPO

By Melissa Fassbender contact

- Last updated on GMT

(Image: iStock)
(Image: iStock)
With the on-boarding of the global private equity investor, Advent International, inVentiv has canceled its previously planned IPO.

Per the agreement, announced today, Advent International will make a material equity investment in inVentiv Health, valuing the company at $3.8bn on a cash-free, debt-free basis.

The transaction is expected to be completed in the fourth quarter of 2016.

Michael Bell, Chairman and Chief Executive Officer of inVentiv Health, commented in a press release that the investment will allow the company to navigate the “increasingly complex scientific and regulatory environment​.”

inVentiv did not respond to a request for comment.

According to the company, "As a result of signing the transaction, inVentiv Group Holdings, Inc., the indirect parent company of inVentiv Health, does not plan to pursue an initial public offering of its common stock at this time​."

As Outsourcing-Pharma.com previously reported​, inVentiv Group Holding filed an S1 with the Securities and Exchange Commission (SEC) in April of this year. The company was seeking to raise $100m by listing on either the New York Stock Exchange or the NASDAQ Global Market.

Related news

Show more

Related products

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...

lyo_vials

Process Development for Lyophilized Products

Baxter BioPharma Solutions | 30-Oct-2017 | Application Note

Baxter approaches formulation and process development with the intention of identifying the failure points for the product. Knowing where the product fails...

Ocopeptides

Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers